Warnings, Columns-Drugs & Supplements, November 2005

November 3, 2005

Eli Lilly and Centocor Discontinue ReoPro Clinical Trial HORSHAM, Pa. - Centocor Inc. and Eli Lilly & Co. have permanently discontinued patient enrollment in phase 3 of its ReoPro® (abciximab) clinical trial. ReoPro was under clinical trial for the treatment of acute ischemic stroke. The trial's independent Safety and Efficacy Monitoring Committee (SEMC) for the Abciximab in Emergent Stroke Treatment Trial-II recommended that the study discontinue enrollment, Eli Lilly and Centocor said, noting they agreed with the recommendation. Eli Lilly and Centocor temporarily suspended enrollment on Oct. 4, following a safety concern raised by the … Subscribe Now Purchase Article for $40.00 Registered User Log In Email Address Password Login Forgot your username or password? UPCOMING CONFERENCES HarrisMartin's MDL Conference: Video Game Addiction and the Latest Mass Tort Updates May 29, 2024 - Salt Lake City, UT The Grand America Hotel MORE DETAILS HarrisMartin's Mass Tort Settlements Conference - Sponsored by Milestone June 27, 2024 - Buffalo, NY The Richardson Hotel Buffalo MORE DETAILS Sign Up For Email Alerts × Email address Publications Asbestos Benzene & Emerging Toxic Torts Litigation Camp Lejeune & Water Contamination Drugs & Medical Devices MDL Mass Tort & Class Action Monitor Reinsurance & Arbitration Talcum Powder Litigation Report Close Submit